Tourmaline Bio (TRML) | Stock Overview & Key Data
Tourmaline Bio Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $198.20 on June 7, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Tourmaline Bio
TRML
|
1.23B Small-cap | 0.04% | 0.31% | 105.57% | 178.79% | 280.19% | 82.43% | 190.79% | -70.47% | -70.47% | -70.47% | -70.47% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.03% | -0.35% | -9.68% | -7.51% | -5.26% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -1.40% | -12.73% | -19.27% | -14.47% | -20.27% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Vericel
VCEL
|
1.75B Small-cap | 1.37% | -4.80% | 1.02% | -7.09% | -2.44% | -19.30% | 1.21% | -40.16% | 1,129.89% | -45.72% | -84.22% |
|
Harmony Biosciences
HRMY
|
1.86B Small-cap | 4.36% | -1.50% | 13.55% | -13.24% | -14.13% | -8.43% | -10.23% | -4.82% | -12.25% | -12.25% | -12.25% |
|
Immunocore Holdings
IMCR
|
1.49B Small-cap | 0.46% | 0.46% | -11.46% | -24.37% | -15.19% | -21.07% | -48.73% | -26.02% | -33.13% | -33.13% | -33.13% |
Ownership & Short Interest
Calculate Your Tourmaline Bio Investment Returns
Long-Term Investment Performance Analysis
Tourmaline Bio stock price in May 2021 was $162.50, A $1,000.00 lump sum investment in Tourmaline Bio made 4 years ago would be worth approximately $295.26 today, representing a negative return of -70.47%. This translates to an annualized return (CAGR) of -23.78%.
4 Years 5 Months Investment Scenario (May 2021 - Oct 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is TRML's 52-week high and low?
- In the last 52 weeks, Tourmaline Bio reached a high of $48.27 (on September 29, 2025) and a low of $11.56 (on April 10, 2025).
- What is the market cap and P/E ratio for TRML?
- Curious about Tourmaline Bio's size and valuation? Its market capitalization stands at 1.23B. When it comes to valuation, the P/E ratio (trailing twelve months) is -16.60, and the forward P/E (looking ahead) is -13.18.
- Does TRML pay dividends? If so, what's the yield?
- As for dividends, Tourmaline Bio isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Tourmaline Bio's main competitors or similar companies to consider before investing?
When looking at Tourmaline Bio, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Vericel
VCEL1.75B Healthcare Biotechnology -19.30% 1.21% Harmony Biosciences
HRMY1.86B Healthcare Biotechnology -8.43% -10.23% Immunocore Holdings
IMCR1.49B Healthcare Biotechnology -21.07% -48.73% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Tourmaline Bio Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Tourmaline Bio's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -29.62%, the Debt to Equity ratio from the most recent quarter is 0.06, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for TRML?
- Looking at Tourmaline Bio's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of TRML stock is held by insiders and institutions?
- Wondering who owns Tourmaline Bio stock? Company insiders (like executives and directors) hold about 14.62% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 89.13%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.